Ferric Derisomaltose (Iron Isomaltoside) Versus Iron Sucrose for Treatment of Iron Deficiency in Pregnancy

Recruiting Phase 3 Interventional Study
Iron Deficiency Anaemia in Childbirth
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 50
Sex
Female
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
280 (estimated)
Sponsor
Saskatchewan Health Authority - Regina Area · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Ion deficiency anemia (IDA) is associated with poor neonatal outcomes and maternal morbidity. Iron replacement may be done with oral iron or intravenous iron, with intravenous iron being utilized later in pregnancy or if there is an inadequate response to oral iron in the first trimester. In Canada, iron sucrose has been used, however iron isomaltoside is as safe as other formulations of IV iron b…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * 18 years of age and over * Pregnancy with Gestational age ≥13 weeks * Iron deficiency anemia defined as: * Hemoglobin less than or equal to 110g/L and * Serum ferritin less than 30ng/mL or * Iron Saturation (Iron/TIBC) less than 20% * Willing to participate and attend all plan…
Contacts

Ryan Lett, MD FRCPC

306-766-3491

ryan.lett@saskhealthuauthority.ca

CONTACT

Sarah Smith, MD, BSc

306-352-4963

sarah.Naden.Smith@gmail.com

CONTACT